



Review

Gene Therapy with Herpes Simplex Virus Vectors

DAVID S. LATCHMAN

Department of Molecular Pathology, Windeyer Institute of Medical Sciences, University College London, Windeyer Building, Cleveland Street, London W1P 6DB, UK

Abstract. Gene delivery to the nervous system represents perhaps the ultimate challenge of gene therapy in view of the complexity of this system, the wide variety of intractable neurological diseases and the need to deliver the gene to non-dividing cells. Although a variety of systems for such gene delivery are under development, herpes simplex virus has unique advantages in terms of its large genome size and its ability to enter a latent state in neuronal cells. Considerable progress has been made in the effective disablement of this virus whilst retaining its ability to deliver genes and in producing long term expression of the foreign gene. Although much remains to be achieved in the further disablement of the virus and its testing in rodent and primate models of human diseases, it is likely that these viruses may ultimately be of use in human gene therapy procedures for otherwise intractable neurological diseases.

Key words: gene therapy; herpes simplex virus; virus vectors.

The term “gene therapy” is used to describe the delivery of a gene or genes to an individual with the aim of achieving a therapeutic benefit. For example, it is evident that where an individual is suffering from the effects of a genetic disease caused by a mutation in a specific gene, delivery of a functional copy of that gene would, in many cases, provide effective relief of the disease. As well as being applicable to such genetic diseases, the gene therapy approach is also applicable to situations other than those where the primary genetic defect is understood. Thus, for example, gene therapy for cancer can involve the delivery of genes which stimulate an immune response to the tumor cells or which allow a non-toxic pro-drug to be converted to a toxic form by the cancer cell, thereby killing the cell. Hence, gene therapy can involve the delivery of genes which are of therapeutic benefit in the disease regardless of whether the disease has a genetic component or whether such a genetic component is fully understood.

This second type of gene therapy is particularly ap-

plicable in diseases of the nervous system where many of the complex diseases either do not have a simple genetic basis or that basis is not understood. Thus, for example, it has been shown that the symptoms of Parkinson’s disease can be relieved both in animal models and human individuals by the transplantation of foetal neurons, because such neurons provide a source of dopamine to replace the deficit of this substance caused by the loss of dopaminergic neurons during the course of the disease (BACKLUND et al.²). Hence, gene therapy for Parkinson’s disease could be attempted by delivering the gene encoding tyrosine hydroxylase which is the rate-limiting enzyme for dopamine production. Similarly, it would be possible to deliver the gene encoding glial-derived neurotrophic factor, since this factor has been shown to promote the survival of dopaminergic neurons and, hence, could be used to arrest the progressive loss of dopaminergic neurons which is characteristic of the disease (OPACKA-JUFFRY et al.³¹).

These possibilities have led numerous laboratories

to attempt to develop means of effectively delivering genes to different organs *in vivo*. Clearly, the simplest method of delivering genes to any organ would be the direct injection of DNA in a standard plasmid vector. However, such methods have proved to be of relatively low efficiency for organs other than skeletal muscle. Indeed, even when the DNA is coated with cationic liposomes to enhance gene delivery, only relatively low levels of gene expression are obtained following injection into the brain, for example (TSUDA and IMAOKEA³⁶).

Thus, many laboratories have turned their attention to virus vectors, since viruses naturally deliver their genetic material into the cells of the organisms which they infect. Unfortunately, the retroviral vectors based on Moloney murine leukemia virus, which are used in many gene delivery experiments, will not infect non-dividing cells and, hence, cannot be used for gene delivery to the many tissues, including the brain, which contain predominantly non-dividing cells. However, lentiviral vectors based on the human immunodeficiency virus (HIV) type of retrovirus, adenovirus, adeno-associated virus and herpes simplex virus (HSV) have all been used as gene delivery vectors capable of delivering genes to non-dividing cells in the brain.

In comparing such vectors in terms of their genome size (Table 1) it is immediately apparent that HSV has a much larger genome than any of the other viruses. This is of particular importance, since a virus will only package the appropriate size of nucleic acid into a virus particle. Hence, viruses with small genome sizes cannot accept very large DNA inserts even when the majority of their genes are eliminated. This is of particular significance when it is necessary to introduce a large gene into cells or when effective therapy may require the delivery of more than one gene. Thus, for example, when adenovirus vectors were used in an animal model of motor neuron disease, effective therapy required both neurotrophin-3 and ciliary neurotrophic factor, which had to be delivered in two separate adenovirus vectors (HAASE et al.¹⁶). This would not have been necessary with HSV due to its much larger genome size.

In addition, whilst all the viruses can infect neuronal cells, only HSV naturally infects neuronal cells as part

of its normal life cycle. Indeed, following initial infection at the periphery, the virus migrates up the sensory nerve processes innervating the site of initial infection and establishes life-long latent infections of the neuronal cell bodies without in any way damaging the neuron or compromising neurological function (for review see ROIZMAN and SEARS³³, LATCHMAN²²). Such latent infections serve as a reservoir for further infections at the periphery following reactivation of the infection, but such reactivation, once again, does not apparently damage the neuronal cell.

Hence, this ability to deliver its DNA to neuronal cells without causing any damage renders the virus ideal for similarly delivering a foreign gene which it is necessary to express within the neuronal cell. Of course, in order to achieve this it will be necessary to disable the virus so that it can no longer conduct the lytic replication which produces peripheral facial and genital sores. This is particularly true since direct injection of virus into the brain results in lytic replication leading to encephalitis and rapid death. Therefore, if advantage is to be taken of the ability of the virus to enter a latent state in neuronal cells, the potentially damaging effects of lytic replication must first be eliminated.

Of course it is essential to do this in a manner which still allows the virus to be grown up so that stocks can be prepared for *in vivo* injection. It is this requirement to disable the virus for use *in vivo* whilst still allowing stocks to be prepared *in vitro* which constitutes the essential problem in effectively disabling the virus. Two basic methods of achieving this have been proposed and these will be discussed in turn.

The first method involves the inactivation of a virus gene which is essential for lytic replication in all cell types. The most frequently inactivated gene in vectors of this type is that encoding the essential immediate early protein ICP4 (CHIOCCA et al.⁵, DOBSON et al.¹²). It is also possible to inactivate the other essential immediate early gene which encodes the viral ICP27 protein (SACKS et al.³⁴). Removal of either of these genes effectively renders the virus incapable of lytic replication in any cell type and it will not, therefore, produce encephalitis when injected into the brain.

The problem evidently remains, however, of growing these viruses in order to produce sufficient stocks. This is achieved by growing the virus on cell lines which have been artificially engineered by introduction of the gene encoding ICP4 or ICP27 and, therefore, allowing lytic growth of the virus. Although this procedure does allow the virus stocks to be grown up, it suffers from the disadvantage that recombination can

Table 1. Genome size of potential virus vectors for the nervous system

Adeno-associated virus	8 500 base pairs
Adenovirus	35 000 base pairs
Herpes simplex virus	150 000 base pairs
Lentivirus	10 000 base pairs

occur between the defective virus genome lacking functional ICP4 or ICP27 and the functional ICP4 or ICP27 gene in the cell line. This will evidently result in the regeneration of dangerous wild-type virus.

To overcome this problem, an alternative approach is to inactivate a virus gene which is necessary for replication in non-dividing cells such as neurons but is not required for replication in dividing cell types. Hence, the virus will not produce encephalitis since it will not replicate lytically in the brain, but stocks can readily be grown on dividing cells *in vitro*. Because of the advantages of this method, our laboratory has utilized a virus strain lacking the gene encoding ICP34.5. The removal of this gene renders the virus non-neurovirulent upon injection into the brain but continues to allow it to replicate on dividing cells (MACLEAN et al.²⁷). We have introduced a marker β -galactosidase into this vector and shown that it is able to deliver genes to the central and peripheral nervous systems following direct injection into the brain or the footpad of mice, respectively (COFFIN et al.⁸).

This system thus combines the ability of the virus to be grown up in culture without a complementing virus gene expressed in a cell line, with the lack of damaging encephalitis upon injection into the brain allowing gene transfer without damaging side effects. Unfortunately, however, in these experiments only a relatively small number of cells in the brain successfully expressed the marker β -galactosidase following injection (COFFIN et al.⁸). We therefore developed this vector further by inactivating also the gene encoding the viral ICP27 protein, thereby introducing two defects into the virus genome. Very surprisingly, the resulting virus not only produced considerably less damage when injected into the brain *in vivo*, but it was also capable of a much higher efficiency of gene delivery with approximately one thousand fold more neurons expressing the marker gene than with the single mutant virus lacking only functional ICP34.5. (HOWARD et al.¹⁹). This double mutant virus, therefore, has both added safety, since it contains two disabling mutations, but is also a much higher efficiency gene delivery vector.

This virus does, however, have to be grown on a cell line which artificially expresses ICP27, since this protein is essential for lytic growth of the virus on all cell types (SACKS et al.³⁴). The possibility of recombination resulting in a functional ICP27 gene being regenerated within the virus is minimised, however, by completely deleting the ICP27 gene from the virus and ensuring that there is no overlap between the DNA sequences remaining in the virus genome and those contained within the cell line. Moreover, even if a rare

recombination event were to occur, this would still not regenerate a wild-type virus, since the resulting virus would continue to lack ICP34.5 and would still not cause a damaging encephalitis.

Hence, this doubly disabled virus represents a relatively safe and efficient gene delivery vector which can be used as a platform for further disablement by deleting, for example, the gene encoding the other essential immediate early protein ICP4 and may, therefore, result ultimately in a virus which is safe enough for therapeutic use in humans.

Once the virus has been effectively disabled, it is possible to use it as a gene delivery vehicle. One approach to this utilised by our laboratory will be discussed here and involves the introduction of the exogenous gene into the virus by recombination. An alternative approach using so called "amplicon" vectors is discussed extensively elsewhere (LATCHMAN²³, COFFIN and LATCHMAN⁷, LEIB and OLIVO²⁴, FINK et al.¹⁴, KENNEDY²¹).

In the recombination method the foreign gene of interest together with an appropriate promoter is flanked by two adjacent regions of the virus genome in a plasmid vector. If this vector is then introduced into cells by transfection together with full length viral DNA, recombination will occur between the viral DNA in the plasmid and the equivalent sequences in the virus, resulting in the insertion of the gene into the virus. This method was first used to introduce marker genes such as the β -galactosidase gene (HO and MOCARSKI¹⁷) or the hypoxanthine phosphoribosyltransferase gene (PALELLA et al.³²) into the virus genome and viruses constructed in this manner have been shown to effectively deliver such genes to the central and peripheral nervous systems *in vivo* (BLOOM et al.³, DOBSON et al.¹²).

Following recombination, some virus particles will contain recombinant virus having the gene of interest, whilst others will contain the original non-recombinant virus. However, it is relatively easy to separate these two types of viruses. Thus, both the recombinant and non-recombinant viruses will form plaques on suitable cell lines which complement any defects in the vector and the recombinant virus can, therefore, be purified provided it can be distinguished from the non-recombinant virus. This can be achieved, for example, by introducing the gene of interest into the thymidine kinase locus of the virus, thereby inactivating this locus and rendering the resulting virus resistant to the effects of the anti-herpes drug acyclovir (HO and MOCARSKI¹⁷, PALELLA et al.³²). Alternatively, the recombinant virus can be distinguished on the basis that it contains a readily

assayable marker gene such as β -galactosidase either alone or in association with the gene of interest. If this cannot be achieved, it is also possible in all cases to grow virus from individual plaques and identify those carrying the gene of interest by southern blot hybridization.

However, before such viruses can be used effectively for gene therapy, it will be necessary to overcome another obstacle. Thus, many of the applications of gene therapy, for example in the nervous system, such as the treatment of Parkinson's disease will require long-term expression of the therapeutic gene. Unfortunately, however, during the onset of latent infection the virus shuts down the expression of virtually all of its own genes in order to enter a virtually silent latent state (for review see ROIZMAN and SEARS³³, LATCHMAN²²). This shut-down of gene expression also occurs for any exogenous genes which are introduced into the virus genome either under the control of the viruses own promoters, other virus promoters such as the immediate early promoter of cytomegalovirus, or a variety of cellular promoters (HO and MOCARSKI¹⁸, PALELLA et al.³², FINK et al.¹⁴, LOKENSGARD et al.²⁵). This results in expression of the foreign gene being observed for only a few days at the most.

Clearly, some means must be found of overcoming this problem if HSV vectors are to be used successfully in a variety of diseases where long term expression of the therapeutic gene will be required. One approach to this problem involves taking advantage of the fact that a small region of the HSV genome remains active during latency, producing the so-called latency-associated transcripts (LATs) (CROEN et al.¹⁰, STEVENS et al.³⁵). The expression of these LATs is driven by two adjacent promoters known as LATP1 and LATP2 and a number of laboratories have attempted to use these to drive long term expression of a foreign gene. This has been achieved either by inserting the foreign gene into the LAT region, hence placing it under the control of the LAT promoters, or by introducing the foreign gene linked to LATP1 or P2 into another region of the genome.

In general, experiments with LATP1 have indicated that it is not sufficient for long-term expression either when a gene is inserted directly downstream of it into the LAT locus or when a LATP1 promoter linked to the β -galactosidase gene is inserted into another site in the HSV genome (MARGOLIS et al.^{28, 29}, DOBSON et al.¹¹). In contrast, the LATP 2 promoter does appear to give much longer term expression either within the LAT region or elsewhere, although such expression is relatively weak (HO and MOCARSKI¹⁸, GOINS et al.¹⁵).

To overcome these difficulties, our laboratory has explored the possibility of whether LATP2 could act as an enhancer element conferring long term expression upon a strongly active promoter. Thus, we have linked LATP2 to the very strong cytomegalovirus immediate early promoter, which normally gives only very short-term expression within an HSV vector, and shown that this combination can direct strong long-term expression when introduced into both the central and peripheral nervous systems. This is likely to be achieved by the LATP2 promoter acting as a signal to maintain the viral chromatin in its immediate vicinity in an open configuration consistent with transcription, thereby allowing the CMV IE promoter to produce high levels of transcription in the long term.

We are currently exploring the possibility of also linking LATP2 to cellular promoters with cell-type specific patterns of activity in order to determine whether such cell-type specific activity could be produced in the long-term within a virus vector by use of the P2 promoter. The use of the P2 promoter has another advantage, however, in that, like classical enhancer elements, it can act bi-directionally and can, therefore, produce long term expression of two genes, each under the control of their own promoters in opposite orientations with the P2 element contained at the centre of the construct. This is of particular importance where it is desired to produce long-term expression of two genes and could be used, for example, where maximal therapeutic efficiency requires two genes to be successfully expressed.

In addition, however, it could be used to express both a marker gene and a gene of therapeutic interest. This would, for example, facilitate purification of the virus away from non-recombinant virus (see above) on the basis of its expression of the marker gene with its subsequent use to express the therapeutic gene.

Another example of the use of such a virus containing both a marker gene and a therapeutic gene would be in a situation where it is necessary *in vitro* to deliver a gene to a population of cells in culture with subsequent reinsertion of these cells into a patient. Thus, many cells for which it is desired to achieve this, such as bone marrow stem cells or dendritic cells, are extremely difficult to transduce with exogenous genes. In the system proposed, the virus expressing two genes would be used to infect such cells and the successfully infected cells could be sorted on the basis of their expression of a reporter gene, producing a 100% pure population expressing the therapeutic gene for reintroduction into the patient.

We have shown the feasibility of this procedure by utilizing a virus which expresses both green fluorescent

protein (GFP) and β -galactosidase and showing that sorting of the infected cells on the basis of their expression of GFP results in a 100% pure population of cells expressing β -galactosidase (COFFIN et al.⁹).

The progress made with disabled recombinant HSV vectors indicates that they represent an effective system for gene delivery. This is particularly so with the recent finding that such viruses do not recombine or reactivate endogenous latent HSV upon introduction into the brain (WANG et al.³⁸). This indicates that such a reactivation of wild-type virus already contained within the patient is unlikely to be a problem with such gene therapy vectors. Hence, the progress made with the disabling of the virus whilst retaining its efficiency in gene delivery and in obtaining long term expression offers hope that such viruses may be of ultimate use therapeutically.

Indeed, in our laboratory we have already constructed viruses expressing both tyrosine hydroxylase and the neurotrophic factor GDNF, which has a protective effect on dopaminergic neurons (OPACKA-JUFFRY et al.³¹). These viruses have been successfully used to express the appropriate genes and produce a reduction in rotational behavior in the 6-hydroxydopamine model of Parkinson's disease. Similarly, we have utilized these viruses to express the genes encoding individual heat shock proteins (hsp). As with delivery of hsp genes by standard transfection of plasmid constructs (AMIN et al.¹, WYATT et al.³⁹), such over-expression, for example, of the 70 kDa heat shock protein (hsp 70) can protect cultured neuronal cells from subsequent exposure to thermal stress or ischemia. Moreover, over-expression of the 27 kDa heat shock protein (hsp27) protected the cells not only against thermal or ischemic stress, but also against stimuli which induce apoptosis, which was not observed with hsp70 (WAGSTAFF et al.³⁷). Most importantly, the protective effect observed in these experiments was significant not only compared to a virus expressing a marker gene alone, but also to samples of cells which were not treated prior to exposure to the stressful stimuli. Hence, the virus does not produce significant damaging effects itself and can deliver a foreign gene with an appropriate protective effect.

In similar experiments, we also observed a protective effect when these viruses expressing hsp were used to infect cells of cardiac origin (BRAR et al.⁶). This illustrates that HSV can also be used to deliver genes to other cell types and organs. Thus, we have previously shown that the virus can effectively deliver a marker gene to the heart *in vivo* (COFFIN et al.⁶) and similar results have also been observed in skeletal muscle (HUARD and GLORIOSO²⁰ 1995) and in liver cells (LU et al.²⁶). Moreover, the ability to deliver to dendritic

cells (see above and COFFIN et al.⁹) is of particular importance in view of the high efficiency of antigen presentation by these cells which could be of use in cancer therapy.

Hence, whilst this review has concentrated on gene delivery to neuronal cells because of the particular applicability of HSV to this relatively difficult problem, the development of HSV vectors may also be of use for gene delivery to a variety of other tissues and cell types.

References

1. AMIN V., CUMMING D. V. E. and LATCHMAN D. S. (1996): Over-expression of heat shock protein 70 protects neuronal cells against both thermal and ischaemic stress but with different efficiencies. *Neurosci. Lett.* **206**, 45–48.
2. BACKLUND E. -O., GRANDBERG P. -O., HAMBERGER B., KNUTSON E., MARTENSSON A., SEDIRALL G., SEIGAR A. and OLSON L. (1985): Transplantation of adrenal medulla tissue to striatum in Parkinsonism. *J. Neurosurg.*, **62**, 169–173.
3. BLOOM D. C., MAIDMENT N. T., TAN A., DISSETTE V. B., FELDMAN L. T. and STEVENS J. G. (1995): Long term expression of a reporter gene from latent herpes simplex virus in the rat hippocampus. *Mol. Brain Res.*, **31**, 48–60.
4. BRAR B. S., STEPHANOU A., WAGSTAFF M. J. D., COFFIN R. S., MARBER M. S., ENGELMANN G. and LATCHMAN D. S. (1999): Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or ischaemic stress. *J. Mol. Cell. Cardiol.*, **31**, 135–146.
5. CHIOCCA A. E., CHOI B. B., CAI W., DE LUCA N. A., SCHAFFER P. A., DI FIGLIA M., BREAKFIELD X. O. and MARTUZA R. L. (1990): Transfer and expression of the lac Z gene in rat brain neurons by herpes simplex virus mutants. *N. Biologist*, **266**, 739–746.
6. COFFIN R. S., HOWARD M. K., CUMMING D. V. E., DOLLERY C. M., MCEWAN J., YELLON D. M., MARBER M. S., MACLEAN A. R., BROWN S. M. and LATCHMAN D. S. (1996): Gene delivery to cardiac cells *in vitro* and *in vivo* using herpes simplex virus vectors. *Gene Ther.*, **3**, 560–566.
7. COFFIN R. S. and LATCHMAN D. S. (1996): Herpes simplex virus based vectors. In LATCHMAN D. S. (ed.): *Genetic manipulation of the nervous system*. Academic Press, London, 99–114.
8. COFFIN R. S., MACLEAN A. R., LATCHMAN D. S. and BROWN S. M. (1996): Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors. *Gene Ther.*, **3**, 886–891.
9. COFFIN R. S., THOMAS S. K., THOMAS N. S. B., LILLEY C. E., PIZZEY A. R., GRIFFITHS C. H., GIBB B. J., WAGSTAFF M. J. D., INGES S. J., BINKS M. H., CHAIN B. M., THRASHER A. J., RUTAUULT K. and LATCHMAN D. S. (1998): Pure populations of transduced primary human cells can be produced using GFP expressing herpes virus vectors and flow cytometry. *Gene Ther.*, **5**, 718–722.
10. CROEN K. D., OSTROVE J. M., DRAGOVIC L. J., SMIALEK J. E. and STRAUS S. E. (1987): Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene anti-sense transcript by *in situ* hybridization. *N. Engl. J. Med.*, **317**, 1427–1432.

11. DOBSON A. T., MARGOLIS T. P., GOMES W. A. and FELDMAN L. T. (1995): *In vivo* deletion analysis of the herpes simplex virus type 1 latency associated transcript promoter. *J. Virol.*, **69**, 2264–2270.
12. DOBSON A. T., MARGOLIS T. P., SEDARATI F., STEVENS J. G. and FELDMAN L. T. (1990): A latent nonpathogenic HSV-1 derived vector stably expresses β galactosidase in mouse neurons. *Neuron*, **5**, 353–360.
13. FINK D. J., DE LUCA N. A., GOINS W. F. and GLORIOSO J. C. (1996): Gene transfer to neurons using herpes simplex virus-based vectors. *Annu. Rev. Neurosci.*, **19**, 265–287.
14. FINK D. J., STERNBERG L. R., WEBER P. C., MATA M., GOINS W. F. and GLORIOSO J. C. (1992): *In vivo* expression of β -galactosidase in hippocampal neurons by HSV-mediated gene transfer. *Hum. Gene Ther.*, **3**, 11–19.
15. GOINS W. F., STERNBERG L. R., CROEN K. D., KRAUSE P. R., HENDRICKS R. L., FINK D. J., STRAUS S. E., LEVINE M. and GLORIOSO J. C. (1994): A novel latency-associated promoter is continued within the herpes simplex virus type 1 UL flanking repeats. *J. Virol.*, **68**, 2239–2252.
16. HAASE G., KENNEL P., PETTMANN B., VIGNE E., AKLI A., REWAH F., SCHMALBRUCH H. and KAHN A. (1997): Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. *Nat. Med.*, **3**, 429–436.
17. HO D. Y. and MOCARSKI E. S. (1988): β -Galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus infected mouse. *Virology*, **167**, 279–283.
18. HO D. Y. and MOCARSKI E. S. (1989): Herpes simplex virus latent RNA (Lat) is not required for latent infection in the mouse. *Proc. Natl. Acad. Sci. USA*, **86**, 7596–7600.
19. HOWARD M. K., KERSHAW T., GIBB B., STOREY N., MACLEAN A. R., ZENG B.-Y., TEL B. C., JENNER P., BROWN S. M., WOOLF C. J., ANDERSON P. N., COFFIN R. S. and LATCHMAN D. S. (1998): High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5. *Gene Ther.*, **5**, 1137–1147.
20. HUARD J. and GLORIOSO J. C. (1995): Herpes simplex virus type 1 vector mediated gene transfer to muscle. *Gene Ther.*, **2**, 385–392.
21. KENNEDY G. E. (1997): Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. *Brain*, **120**, 1245–1259.
22. LATCHMAN D. S. (1990): Molecular biology of herpes simplex virus latency. *Int. J. Exp. Pathol.*, **71**, 133–141.
23. LATCHMAN D. S. (1994): Herpes simplex virus vectors for gene therapy. *Mol. Biotechnol.*, **2**, 179–195.
24. LEIB D. A. and OLIVO P. D. (1993): Gene delivery to neurons: is herpes simplex virus the right tool for the job? *Bioessays*, **15**, 547–554.
25. LOKENSGARD J. R., BLOOM D. C., DOBSON A. T. and FELDMAN L. T. (1994): Long term promoter activity during herpes simplex virus latency. *J. Virol.*, **68**, 7148–7158.
26. LU B., GUPTA S. and FEDEROFF H. (1995): *Ex vivo* hepatic gene transfer in mouse using a defective herpes simplex virus-1 vector. *Hepatology*, **21**, 752–759.
27. MACLEAN A. R., FAREED M. U., ROBERTSON L., HARLAND J. and BROWN S. M. (1991): Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate-early gene 1 and the “a” sequence. *J. Gen. Virol.*, **72**, 631–639.
28. MARGOLIS T. P., BLOOM D. C., DOBSON A. T., FELDMAN L. T. and STEVENS J. G. (1993): Decreased reporter gene expression during latent infection with HSV LAT promoter constructs. *Virology*, **197**, 585–592.
29. MARGOLIS T. P., SEDARATI F., DOBSON A. T., FELDMAN L. T. and STEVENS J. G. (1992): Pathways of viral gene expression during acute neuronal infection with HSV-1. *Virology*, **189**, 150–160.
30. MILLER A. G., ADAM M. A. and MILLER A. D. (1990): Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. *Mol. Cell. Biol.*, **10**, 4239–4242.
31. OPACKA-JUFFRY J., ASHWORTH S., HUME S. P., MARTIN D., BROOKS D. J. and BLUNT S. B. (1995): rhGDNF protects nigrostriatal DA neurons against the neurotoxin 6-OHDA: an *in vivo* study using microdialysis and positron emission tomography. *Neuroreport*, **7**, 348–352.
32. PALELLA T. D., SILVERMAN L. J., SCHROLL C. T., HOMA F. L., LEVINE M. and KELLY W. N. (1988): Herpes simplex virus mediated human hypoxanthine-guanine phosphoribosyltransferase gene transfer into neuronal cells. *Mol. Cell. Biol.*, **8**, 457–460.
33. ROIZMAN B. and SEARS A. E. (1998): An inquiry into the mechanisms of herpes simplex virus latency. *Annu. Rev. Microbiol.*, **41**, 543–571.
34. SACKS W. R., GREENE C. C., ASCHMANN D. P. and SCHAFER P. A. (1985): Herpes simplex virus type 1 ICP27 is an essential regulatory protein. *J. Virol.*, **55**, 796–805.
35. STEVENS J. G., WAGNER E. K., DEVI-RAO G. B., COOK M. L. and FELDMAN L. T. (1987): RNA complementary to a herpes virus alpha gene mRNA is prominent in latently infected neurons. *Science*, **235**, 1056–1059.
36. TSUDA M. and IMAOKA T. (1996): Direct injection of plasmid DNA into the brain. In LATCHMAN D. S. (ed.): *Genetic manipulation of the nervous system*. Academic Press, London, 235–248.
37. WAGSTAFF M. J. D., COLLACO-MORAES Y., SMITH J., DE BELEROCHE J. S., COFFIN R. S. and LATCHMAN D. S. (1999): Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector. *J. Biol. Chem.*, **274**, 5061–5069.
38. WANG Q., GUO J. and JIA W. (1997): Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. *Gene Ther.*, **4**, 1300–1304.
39. WYATT S., MAILHOS C. and LATCHMAN D. S. (1996): Trigeminal ganglion neurons are protected by the heat shock proteins hsp70 and hsp90 from thermal stress but not from programmed cell death following NGF withdrawal. *Brain Res.*, **39**, 52–56.

Received in February 1999

Accepted in April 1999